Mitochondria-targeted atovagone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug
Grant
US12594283B2
Kind: B2
Apr 07, 2026
Assignee
The Medical College of Wisconsin, Inc.
Inventors
Balaraman Kalyanaraman, Gang Cheng, Micael Joël Hardy
Abstract
The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.
CPC Classifications
A61K 31/66
A61K 31/122
A61K 45/06
A61K 31/662
A61P 35/00
C07C 49/84
C07F 9/535
C07F 9/5435
C07F 9/5456
Filing Date
2020-10-26
Application No.
17770924
Claims
22